Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...

Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR ...

Trastuzumab botidotin has met the primary endpoints of its pivotal Phase 2 trial for 3L+ advanced HER2+ BC based on results from the primary analysis, which the Company used to submit an NDA to the ...

Experts discuss how to facilitate open communication among the patient, caregivers, and the multidisciplinary team to ensure comprehensive care and alignment on treatment goals.

昨天（3月24日）晚间，科伦博泰发布了2024年度业绩报告。报告期内，公司营收19.33亿元，同比增长25.5%；毛利12.74亿元，同比增长67.8%；研发支出12.06亿元，同比增长17%；年度亏损2.67亿元，同比减少53.5%；调整后年度亏损 ...

Experts discuss how to manage fatigue, abdominal pain, and other treatment-related symptoms to maintain or improve quality of life for patients undergoing HER2-targeted therapy and share strategies ...

A father of two has spoken about being diagnosed with what was once referred to as “the old man’s cancer” and has urged men ...

Nadunolimab's potential to mitigate FOLFOX-induced CIPN was assessed among 14 patients across eight cancer types in the CESTAFOUR (NCT05116891) study. Patients treated with 1 mg/kg of nadunolimab ...

• Revenue was approximately RMB1,933.0 million, representing a year-on-year increase of 25.5%. • Gross profit was approximately RMB1,273.7 million, representing a year-on-year increase of 67.8 ...